Iron
is an essential micronutrient for the survival and virulence
of the bacterial pathogen Pseudomonas aeruginosa.
To overcome iron withholding and successfully colonize a host, P. aeruginosa uses a variety of mechanisms to acquire iron,
including the secretion of high-affinity iron chelators (siderophores)
or the uptake and utilization of heme. P. aeruginosa heme oxygenase (HemO) plays pivotal roles in heme sensing, uptake,
and utilization and has emerged as a therapeutic target for the development
of antipseudomonal agents. Using a high-throughput fluorescence quenching
assay combined with minimum inhibitory concentration measurements,
we screened the Selleck Bioactive collection of 2100 compounds and
identified acitretin, a Food and Drug Administration-approved oral
retinoid, as a potent and selective inhibitor of HemO. Acitretin binds
to HemO with a K
D value of 0.10 ±
0.02 μM and inhibits the growth of P. aeruginosa PAO1 with an IC50 of 70 ± 18 μg/mL. In addition,
acitretin showed good selectivity for HemO, which uniquely generates
BVIXβ/δ, over human heme oxygenase (hHO1) and other BVIXα-producing
homologues such as the heme oxygenases from Neisseria meningitidis (nmHO) and Acinetobacter baumannii (abHO). The
binding of acitretin within the HemO active site was confirmed by 1H–15N heteronuclear single-quantum coherence
nuclear magnetic resonance, and molecular modeling provided further
insight into potential interactions of acitretin with residues specific
for orienting heme in the β/δ selective HemO. Moreover,
at 20 μM, acitretin inhibited the enzymatic activity of HemO
in P. aeruginosa cells by >60% and effectively
blocked
the ability of P. aeruginosa to sense and acquire
heme as demonstrated in the β-galactosidase transcriptional
reporter assay.